To examine the clinical relevance of the co-expression of phospho-MARCKS and phospho-p65 in smoke-related lung cancer, we then validated both phospho-MARCKS and phospho-p65 signal abundance in another cohort of lung cancer patients (n = 96) with smoking history (Tables S5, S6 and S7). This evidence concerns the gene MARCKS and lung cancer.